Currently used androgenic formulations for replacement therapy are largely restricted to injectable or skin delivery formulations of testosterone or testosterone esters. Marketed injectable forms of testosterone esters (such as testosterone enanthate, propionate, or cypionate) produce undesirable fluctuations in testosterone blood levels, with supraphysiological concentrations early, and subnormal levels towards the end of the period before the next injection, providing an unsatisfactory profile and in some cases undesired side effects. Skin patches do provide a better blood level profile of testosterone, but skin irritation and daily application still limit the usefulness and acceptability of this form of therapy (1, 20, 21, 22). Oral preparations such as fluoxymesterone and 17-methyltestosterone are not currently used due to concerns about liver toxicity linked to the 17-alkyl group and because of somewhat lower efficacy. Thus, these compounds are considered obsolete (1, 20) and do not represent a viable form of therapy.
The discovery and development of SARMs provides the opportunity to design molecules that are not only orally active, but that target AR in different tissues to elicit the desired activity for each of the key indications benefiting from androgen therapy.
A novel, highly potent, orally active, nonsteroidal tissue selective androgen receptor (AR) modulator (BMS-564929) has been identified, and this compound has been advanced to clinical trials for the treatment of age-related functional decline. BMS-564929 is a subnanomolar AR agonist in vitro, is highly selective for the AR vs. other steroid hormone receptors, and exhibits no significant interactions with SHBG or aromatase. Dose response studies in castrated male rats show that BMS-564929 is substantially more potent than testosterone (T) in stimulating the growth of the levator ani muscle, and unlike T, highly selective for muscle vs. prostate.
SARMS appear to be the future of HRT. They seem to have such a positive safety profile and benign nature that they would throw the T haters into their own version of “roid rage.” Doc
Diandrone is actually a fancy name for DHEA. While Trans-4-Hydroxy-3-Methoxycinnamic Acid is Ferulic Acid which can act as an anti-inflammatory (it is found in whole wheat, brown rice, etc).
SARMs are real, SARM-X by MHP is real crap. It is going to be a little while before real SARMs are available, and you will have to go through your doctor to attain them.
Diandrone is actually a fancy name for DHEA. While Trans-4-Hydroxy-3-Methoxycinnamic Acid is Ferulic Acid which can act as an anti-inflammatory (it is found in whole wheat, brown rice, etc).
SARMs are real, SARM-X by MHP is real crap. It is going to be a little while before real SARMs are available, and you will have to go through your doctor to attain them.[/quote]
Diandrone is actually a fancy name for DHEA. While Trans-4-Hydroxy-3-Methoxycinnamic Acid is Ferulic Acid which can act as an anti-inflammatory (it is found in whole wheat, brown rice, etc).
SARMs are real, SARM-X by MHP is real crap. It is going to be a little while before real SARMs are available, and you will have to go through your doctor to attain them.[/quote]
We may be getting access to these via research chems way before they become FDA approved. Can these be detected in urine?